Cooper Companies Reaches New 52-Week High (COO)

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

NEW YORK ( TheStreet) -- Cooper Companies (NYSE: COO) hit a new 52-week high Friday as it is currently trading at $117.40, above its previous 52-week high of $116.79 with 51,673 shares traded as of 9:36 a.m. ET. Average volume has been 315,600 shares over the past 30 days.

Cooper Companies has a market cap of $5.36 billion and is part of the health care sector and health services industry. Shares are up 22.3% year to date as of the close of trading on Thursday.

The Cooper Companies, Inc. operates as a medical device company worldwide. The company has a P/E ratio of 20.6, above the S&P 500 P/E ratio of 17.7.

  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

TheStreet Ratings rates Cooper Companies as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance, impressive record of earnings per share growth and compelling growth in net income. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. You can view the full Cooper Companies Ratings Report.

See all 52-week high stocks or get investment ideas from our investment research center.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more..
null

If you liked this article you might like

Teva Nailed With S&P Downgrade

Teva Nailed With S&P Downgrade

7 Investment Themes You Can't Afford to Miss for 2018

7 Investment Themes You Can't Afford to Miss for 2018

Teva Still Has Big Problems It Must Deal With in 2018

Teva Still Has Big Problems It Must Deal With in 2018

Teva Closes Higher as Generic Drugmaker Announces Massive Layoffs, Asset Sales

Teva Closes Higher as Generic Drugmaker Announces Massive Layoffs, Asset Sales

The 60-Year-Old Gold Bug and the 25-Year-Old Bitcoin Fan Are Alike: Market Recon

The 60-Year-Old Gold Bug and the 25-Year-Old Bitcoin Fan Are Alike: Market Recon